TARE for HCCHolmium-166 Radioembolization for Advanced Liver Cancer

This study is about exploring the use of Holmium-166 (Ho-166) transarterial radioembolization (TARE), a type of radiation therapy, for treating patients with a form of liver cancer known as hepatocellular carcinoma (HCC). HCC is an aggressive cancer that often develops in people with liver cirrhosis, typically due to long-term viral hepatitis or a condition called metabolic dysfunction-associated fatty liver disease. As HCC advances, treatment options become limited, especially when the cancer has reached advanced stages. The study aims to understand if Ho-166 TARE can offer significant benefits in managing HCC, potentially improving care for those who are not eligible for surgery or liver transplantation. In this study, patients receive Ho-166 TARE treatment, which involves the delivery of tiny particles containing the radioactive isotope Holmium-166 directly to the tumor site through the liver's blood supply. This targeted approach aims to destroy the tumor while minimizing harm to the surrounding healthy liver tissue. The study looks back at the medical records of patients who received this treatment between January 2010 and December 2024. It examines factors like patient demographics, tumor characteristics, side effects of the treatment, and how well the therapy worked. The primary goals are to evaluate the effectiveness of Ho-166 TARE in terms of overall survival and tumor response rate, and to assess its safety compared to other treatment options.